CompletedNCT05870540
BPL-003 safety and efficacy study for resistant depression
About this title
Read the official source — NCT05870540This study evaluated the safety and effectiveness of BPL-003 for people with depression.
Medication studyAges 18–75Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of BPL-003 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 41 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 14, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 196
- Sponsor
- Beckley Psytech Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Australia, United Kingdom, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT05870540
- Official title
Show the full official title
A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, With Open Label Extension, in Patients With Treatment-Resistant Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Rogers, United States · San Diego, United States
33 more locations
- San Francisco, United States
- Santa Monica, United States
- Fort Collins, United States
- Lauderhill, United States
- Atlanta, United States
- Decatur, United States
- Rockville, United States
- Boston, United States
- Berlin, United States
- New York, United States
- Portland, United States
- DeSoto, United States
- Plano, United States
- Draper, United States
- Madison, United States
- Sydney, Australia
- Clayton, Australia
- Melbourne, Australia
- Parkville, Australia
- Berlin, Germany
- Frankfurt am Main, Germany
- Mannheim, Germany
- Tübingen, Germany
- Gdansk, Poland
- Lodz, Poland
- Tuszyn, Poland
- Warsaw, Poland
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Salamanca, Spain
- Exeter, United Kingdom
- London, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of BPL-003 for people with depression.
Who is behind this study?
The study sponsor is Beckley Psytech Limited.
Did this study involve medication?
Yes. The study involved medication, including BPL-003.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
